Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
On-Jee Choi 1 Article
Serological Correlate of Protection in Guinea Pigs for a Recombinant Protective Antigen Anthrax Vaccine Produced from Bacillus brevis
Jeong-Hoon Chun, On-Jee Choi, Min-Hee Cho, Kee-Jong Hong, Won Keun Seong, Hee-Bok Oh, Gi-Eun Rhie
Osong Public Health Res Perspect. 2012;3(3):170-176.   Published online June 30, 2012
DOI: https://doi.org/10.1016/j.phrp.2012.07.006
  • 2,179 View
  • 22 Download
  • 10 Citations
AbstractAbstract PDF
Objective Recombinant protective antigen (rPA) is the active pharmaceutical ingredient of a second generation anthrax vaccine undergoing clinical trials both in Korea and the USA. By using the rPA produced from Bacillus brevis pNU212 expression system, correlations of serological immune response to anthrax protection efficacy were analyzed in a guinea pig model.
Methods
Serological responses of rPA anthrax vaccine were investigated in guinea pigs that were given single or two injections (interval of 4 weeks) of various amounts of rPA combined with aluminumhydroxide adjuvant. Guinea pigs were subsequently challenged by the intramuscular injection with 30 half-lethal doses (30LD50) of virulent Bacillus anthracis spores. Serumantibody titerswere determined by anti-PA IgGELISA and the ability of antibodies to neutralize the cytotoxicity of lethal toxin on J774A.1 cell was measured through the toxin neutralizing antibody (TNA) assay.
Results
To examine correlations between survival rate and antibody titers, correlation between neutralizing antibody titers and the extent of protection was determined. Toxin neutralization titers of at least 1176 were sufficient to confer protection against a dose of 30LD50 of virulent anthrax spores of the H9401 strain. Such consistency in the correlation was not observed from those antibody titers determined by ELISA.
Conclusion
Neutralizing-antibody titers can be used as a surrogate marker.

Citations

Citations to this article as recorded by  
  • A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potential anthrax vaccine candidate
    Jun Ho Jeon, Yeon Hee Kim, Kyung Ae Kim, Yu-Ri Kim, Sun-Je Woo, Ye Jin Choi, Gi-eun Rhie
    BMC Immunology.2021;[Epub]     CrossRef
  • Construction of a bivalent vaccine against anthrax and smallpox using the attenuated vaccinia virus KVAC103
    Deok Bum Park, Bo-Eun Ahn, Hosun Son, Young-Ran Lee, Yu-Ri Kim, Su Kyoung Jo, Jeong-Hoon Chun, Jae-Yon Yu, Myung-Min Choi, Gi-eun Rhie
    BMC Microbiology.2021;[Epub]     CrossRef
  • Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis
    Sean M. Kelly, Kristina R. Larsen, Ross Darling, Andrew C. Petersen, Bryan H. Bellaire, Michael J. Wannemuehler, Balaji Narasimhan
    Vaccine.2021; 39(29): 3862.     CrossRef
  • Current Status and Trends in Prophylaxis and Management of Anthrax Disease
    Vladimir Savransky, Boris Ionin, Joshua Reece
    Pathogens.2020; 9(5): 370.     CrossRef
  • Anthrax prevention through vaccine and post-exposure therapy
    Manish Manish, Shashikala Verma, Divya Kandari, Parul Kulshreshtha, Samer Singh, Rakesh Bhatnagar
    Expert Opinion on Biological Therapy.2020; 20(12): 1405.     CrossRef
  • A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model
    Bo-Eun Ahn, Hee-Won Bae, Hae-Ri Lee, Sun-Je Woo, Ok-Kyu Park, Jun Ho Jeon, Jungchan Park, Gi-eun Rhie
    Biochemical and Biophysical Research Communication.2019; 509(2): 611.     CrossRef
  • Vaccines against anthrax based on recombinant protective antigen: problems and solutions
    Olga A. Kondakova, Nikolai A. Nikitin, Ekaterina A. Evtushenko, Ekaterina M. Ryabchevskaya, Joseph G. Atabekov, Olga V. Karpova
    Expert Review of Vaccines.2019; 18(8): 813.     CrossRef
  • A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes
    Theodor Chitlaru, Ma'ayan Israeli, Shahar Rotem, Uri Elia, Erez Bar-Haim, Sharon Ehrlich, Ofer Cohen, Avigdor Shafferman
    Vaccine.2017; 35(44): 6030.     CrossRef
  • Expression and refolding of the protective antigen of Bacillus anthracis: A model for high-throughput screening of antigenic recombinant protein refolding
    María Elisa Pavan, Esteban Enrique Pavan, Fabián Martín Cairó, María Julia Pettinari
    Revista Argentina de Microbiología.2016; 48(1): 5.     CrossRef
  • Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge withBacillus cereusG9241
    John Palmer, Matt Bell, Christian Darko, Roy Barnewall, Andrea Keane-Myers
    Pathogens and Disease.2014; : n/a.     CrossRef

PHRP : Osong Public Health and Research Perspectives